Zealand Pharma A Quick Ratio (ZEAL) starting from the fourth quarter 2021 to fourth quarter 2020, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Zealand Pharma A  (NASDAQ: ZEAL)

Zealand Pharma A's Quick Ratio

ZEAL's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2021, Quick Ratio deteriorated to 1.75 below Zealand Pharma A's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 480 other companies have achieved higher Quick Ratio than Zealand Pharma A in fourth quarter 2021. While Quick Ratio total ranking has improved so far during the Q4 2021 to 2048, from total ranking in the third quarter 2021 at 2052.

Explain Quick Ratio?
How much Cash & cash equivalents ZEAL´s has?
What are ZEAL´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ZEAL Quick Ratio (Dec 31 2021)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2020)
Q3
Y / Y Current Liabilities Change 71.25 % 1301.92 % 2109.8 % 3619.71 % 391.17 %
Y / Y Cash & cash equivalent Change 10.33 % 490.06 % 603.77 % 770.13 % 65.44 %
Quick Ratio MRQ 1.75 1.78 1.78 1.78 2.72
ZEAL's Total Ranking # 2048 # 2052 # 2071 # 0 #
Seq. Current Liabilities Change -84.57 % 0 % 0 % 1009.55 % 26.35 %
Seq. Cash & cash equivalent Change -84.78 % 0 % 0 % 624.9 % -18.6 %



Quick Ratio fourth quarter 2021 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 481
Healthcare Sector # 865
Overall Market # 2048


Quick Ratio Statistics
High Average Low
1.78 1.78 1.78
(Dec 31 2021)  




Financial Statements
Zealand Pharma A's Current Liabilities $ 100 Millions Visit ZEAL's Balance sheet
Zealand Pharma A's Cash & cash equivalent $ 175 Millions Visit ZEAL's Balance sheet
Source of ZEAL's Sales Visit ZEAL's Sales by Geography


Cumulative Zealand Pharma A's Quick Ratio

ZEAL's Quick Ratio for the trailling 12 Months

ZEAL Quick Ratio

 (Dec 31 2021)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2020)
12 Months
Y / Y Current Liabilities TTM Growth 1250.35 % 1809.65 % 1873.72 % 1409.33 % 340.19 %
Y / Y Cash & cash equivalent TTM Growth 458.46 % 515.44 % 505.69 % 395.44 % 217.73 %
Quick Ratio TTM 1.77 1.8 1.9 2.13 4.29
Total Ranking TTM # 5593 # 1808 # 0 # 0 #
Seq. Current Liabilities TTM Growth 2.08 % 42.96 % 79.12 % 416.58 % 44.36 %
Seq. Cash & cash equivalent TTM Growth 0.45 % 35.99 % 59.19 % 156.81 % 10.7 %

Quick ratio ranking by company, industry and sector >> Back to ZEAL Financial Strength Comparisons >> Go to Compare ZEAL Quick Ratio to its Competitors

On the trailing twelve months basis Due to drop in Current Liabilities in the Q4 2021 to $100.00 millions, cumulative Quick Ratio decreased to 1.77 below the Zealand Pharma A average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 599 other companies have achieved higher Quick Ratio than Zealand Pharma A. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2021 from 1808 to 5593.

Explain Quick Ratio?
How much Cash & cash equivalents ZEAL´s has?
What are ZEAL´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 600
Healthcare Sector # 1193
Within the Market # 5593


trailing twelve months Quick Ratio Statistics
High Average Low
1.78 1.78 1.78
(Dec 31 2021)  




Companies with similar Quick Ratio in the quarter ending Dec 31 2021, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2021 MRQ Cash & cash equivalentDec 31 2021 MRQ Current Liabilities
Tg Therapeutics Inc   4.81 $ 314.763  Millions$ 65.384  Millions
Oncorus Inc   4.80 $ 100.752  Millions$ 20.974  Millions
Proqr Therapeutics N v   4.75 $ 212.240  Millions$ 44.717  Millions
Immunogen inc   4.74 $ 478.750  Millions$ 100.945  Millions
Alaunos Therapeutics Inc   4.74 $ 76.054  Millions$ 16.041  Millions
Contrafect Corporation  4.71 $ 54.285  Millions$ 11.517  Millions
Aveo Pharmaceuticals Inc   4.66 $ 87.326  Millions$ 18.731  Millions
Spyre Therapeutics Inc   4.62 $ 93.128  Millions$ 20.144  Millions
Sonnet Biotherapeutics Holdings Inc   4.53 $ 27.622  Millions$ 6.093  Millions
Oncosec Medical Incorporated  4.53 $ 25.231  Millions$ 5.572  Millions
Biovie Inc   4.53 $ 4.512  Millions$ 0.996  Millions
Verona Pharma Plc  4.53 $ 148.380  Millions$ 32.774  Millions
Adc Therapeutics Sa  4.50 $ 466.544  Millions$ 103.658  Millions
Ac Immune Sa  4.49 $ 89.893  Millions$ 20.026  Millions
Sellas Life Sciences Group Inc   4.48 $ 21.455  Millions$ 4.784  Millions
Panbela Therapeutics Inc   4.46 $ 11.867  Millions$ 2.660  Millions
Ascendis Pharma A  4.46 $ 500.819  Millions$ 112.399  Millions
Travere Therapeutics Inc   4.46 $ 552.882  Millions$ 124.088  Millions
Evelo Biosciences Inc   4.44 $ 68.441  Millions$ 15.411  Millions
Soligenix inc   4.43 $ 26.044  Millions$ 5.882  Millions
Kiniksa Pharmaceuticals International Plc  4.40 $ 182.201  Millions$ 41.443  Millions
Galectin Therapeutics Inc   4.39 $ 39.648  Millions$ 9.033  Millions
Ocean Biomedical Inc   4.36 $ 1.076  Millions$ 0.246  Millions
Harmony Biosciences Holdings inc   4.36 $ 234.309  Millions$ 53.775  Millions
Calithera Biosciences Inc   4.25 $ 59.537  Millions$ 14.006  Millions
Protagonist Therapeutics inc   4.24 $ 326.900  Millions$ 77.175  Millions
Mannkind Corporation  4.22 $ 204.116  Millions$ 48.349  Millions
Ngm Biopharmaceuticals Inc   4.20 $ 366.253  Millions$ 87.225  Millions
Chemocentryx Inc.  4.20 $ 264.492  Millions$ 63.017  Millions
Insmed Inc  4.19 $ 716.782  Millions$ 171.129  Millions

Date modified: 2026-09-09T12:37:48+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.